These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25906832)

  • 1. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.
    Wood BL
    Cytometry B Clin Cytom; 2016 Jan; 90(1):47-53. PubMed ID: 25906832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
    Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
    Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
    Oldaker TA; Wallace PK; Barnett D
    Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
    Gormley NJ; Turley DM; Dickey JS; Farrell AT; Reaman GH; Stafford E; Carrington L; Marti GE
    Cytometry B Clin Cytom; 2016 Jan; 90(1):73-80. PubMed ID: 26108351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
    Rawstron AC; de Tute RM; Haughton J; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease studies by flow cytometry in acute leukemia.
    Campana D; Coustan-Smith E
    Acta Haematol; 2004; 112(1-2):8-15. PubMed ID: 15178999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One tube with eight antibodies for 14-part bone marrow leukocyte differential using flow cytometry.
    Jacob MC; Souvignet A; Pont J; Solly F; Mondet J; Kesr S; Pernollet M; Dumestre-Perard C; Campos L; Cesbron JY
    Cytometry B Clin Cytom; 2017 Jul; 92(4):299-309. PubMed ID: 26990701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
    Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
    Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
    Cui W; Zhang D; Cunningham MT; Tilzer L
    Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
    Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
    Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
    Rawstron AC; Paiva B; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advancements of flow cytometry: new applications in hematology and oncology.
    Woo J; Baumann A; Arguello V
    Expert Rev Mol Diagn; 2014 Jan; 14(1):67-81. PubMed ID: 24308362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Campana D; Coustan-Smith E
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technical issues: flow cytometry and rare event analysis.
    Hedley BD; Keeney M
    Int J Lab Hematol; 2013 Jun; 35(3):344-50. PubMed ID: 23590661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.